Veracyte (VCYT)
Develops molecular tests that guide cancer diagnosis, treatment, and recurrence monitoring.
$43.50
After hours+0.14 (+0.32%)
At close$43.36(+4.43%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 110.79% | 89.06M shares | |
|---|---|---|---|
| 379 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.70% | 1.37M shares | |
| 15 holders · as of Sep 22, 2026 | |||
| Strategic holders | 10.72% | 8.62M shares | |
| 2 holders · as of May 13, 2026 | |||
| Adds to | 123.21% | ||
80.39M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 123.21%; nothing is left for Other.
13F, as of Jun 30, 2026
379 holders · 89.06M shares · 79 new positions · 207 increased · 126 reduced · 42 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.49M | 16.78% | +313.8K | Aug 7, 2026 |
| FMR LLC | 7.70M | 9.58% | −61.1K | Aug 13, 2026 |
| Artisan Partners Limited Partnership | 5.54M | 6.89% | +42.0K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 4.72M | 5.87% | +271.5K | Aug 13, 2026 |
| State Street Corp | 4.70M | 5.84% | −345.5K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 3.59M | 4.47% | +61.7K | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 2.83M | 3.52% | −54.6K | Aug 11, 2026 |
| First Trust Advisors LP | 2.51M | 3.12% | +390.9K | Aug 11, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.20% | 11.93M | 13G | Aug 1, 2025 |
| FMR LLC | 10.10% | 8.06M | 13G | Jun 5, 2026 |
| Artisan Partners Limited Partnership | 8.50% | 6.60M | 13G | Feb 12, 2025 |
| Artisan Partners Asset Management Inc. | 6.90% | 5.50M | 13G | May 13, 2026 |
| State Street Corporation | 6.30% | 5.04M | 13G | May 12, 2026 |
| Vanguard Portfolio Management | 5.67% | 4.51M | 13G | Apr 29, 2026 |
| Vanguard Capital Management | 5.20% | 4.13M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 21, 2026 | John Leiteofficer: Global Chief Commercial Off | Sale | 4,015 | $40.00 | 124,329 |
| Sep 14, 2026 | Jens Holsteindirector | Sale | 5,000 | $40.95 | 27,471 |
| Sep 4, 2026 | Annie McGuireofficer: EVP, General Counsel | Sale · 2 lots | 3,254 | $43.09 | 131,160 |
| Sep 4, 2026 | Rebecca Chambersofficer: Chief Financial Officer | Sale · 2 lots | 3,652 | $43.10 | 166,025 |
| Sep 4, 2026 | Phillip G. Febboofficer: Chief Scientific & Med Officer | Sale · 2 lots | 13,110 | $43.05 | 133,048 |
| Sep 1, 2026 | Muna Bhanjidirector | Sale | 1,864 | $42.97 | 42,718 |
| Jun 18, 2026 | Karin Easthamdirector | Sale · 2 lots | 3,729 | $52.89 | 15,097 |
| Jun 4, 2026 | John Leiteofficer: Global Chief Commercial Off | Sale | 13,975 | $50.07 | 132,305 |
| Jun 4, 2026 | Marc Stapleydirector, officer: Chief Executive Officer | Sale | 138,051 | $50.12 | 440,494 |
| Jun 4, 2026 | Rebecca Chambersofficer: Chief Financial Officer | Sale · 2 lots | 3,561 | $49.73 | 173,280 |
House and Senate disclosures
Not reported.